poster

Bioequivalence and Safety Comparison of Once-Weekly Donepezil Transdermal System With Oral Donepezil: Results of a Phase 1 Pharmacokinetic Study in Healthy Volunteers

Abstract: Oral donepezil is widely prescribed for dementia of the Alzheimer’s type. Donepezil transdermal system (TDS; Adlarity®) was also recently approved. Here, we report bioequivalenc...

01/19/2023

Evaluation of Skin Adhesion and Local Skin Tolerability of Once-Weekly Donepezil Transdermal System: Results of a Phase 1 Trial in Healthy Volunteers

Abstract: Donepezil transdermal system (TDS; Adlarity®) is approved for dementia of the Alzheimer’s type. Reported here are skin-adhesion and skin-tolerability evaluations of donepezil TD...

01/19/2023

A New Methodological Approach to Improve the "Real Word" Effectiveness of Ketamine Infusion Therapy for Treatment-Resistant Depression

Abstract: Objective: Ketamine is recognized as a rapidly acting antidepressant; however, discrepancies exist between the "Efficacy" reported in research studies (70-85%) versus significan...

01/19/2023

Dispelling Myths and Misconceptions Surrounding the Use of Long-acting Injectable Antipsychotic Agents for Treatment of Schizophrenia

Abstract: Introduction: Schizophrenia affects over 3 million people in the United States. Despite data supporting the use of long-acting injectable antipsychotic agents (LAIs), myths and ...

01/19/2023

Effect of Food on Pharmacokinetics of Once-Daily Extended-Release Lorazepam

Abstract: Lorazepam is an allosteric GABA-receptor modulator approved for the treatment of anxiety disorders. Traditionally, it is administered as immediate-release tablets given two or ...

01/19/2023

Pattern of Reports of Headache in Phase 3 Clinical Trials of Lemborexant

Abstract: Introduction: Headache is a frequently reported treatment-emergent adverse event (TEAE) in clinical trials of hypnotics. We evaluated the frequency and timing of TEAEs of headac...

01/19/2023

Relationship Between Daytime Functioning and Fatigue Over 6 Months in Lemborexant-Treated Subjects with Insomnia Disorder

Abstract: Introduction: Study E2006-G000-303 (Study 303; NCT02952820) showed lemborexant (LEM) provided significant benefit vs placebo (PBO) on patient-reported sleep and fatigue severity...

01/19/2023

Impact of AXS-05 (Dextromethorphan-Bupropion), an Oral NMDA Receptor Antagonist, on Anhedonic Symptoms in Major Depressive Disorder

Abstract: Background: Treatments for MDD that can improve both overall depressive and anhedonic symptoms are urgently needed. AXS-05 (dextromethorphan-bupropion) is a novel, oral, inv...

01/19/2023

Efficacy of adjunctive cariprazine across individual depressive symptoms in major depressive disorder: a post-hoc analysis

Abstract: Background: Patients with major depressive disorder (MDD) who have inadequate response to antidepressant treatment (ADT) may require adjunctive therapy. Cariprazine (CAR), a dop...

01/19/2023

Efficacy of Adjunctive Cariprazine on Anxiety Symptoms in Patients With Major Depressive Disorder and Baseline Anxiety: Post Hoc Analysis of a Randomized Controlled Trial

Abstract: Background: Adjunctive cariprazine was evaluated in patients with major depressive disorder (MDD) and inadequate response to monotherapy antidepressant treatment (ADT), stratifi...

01/19/2023

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products